Miaomiao Ge is the Executive Director and Head of Experimental Medicine Oncology Biostatistics at Boehringer Ingelheim. With a Ph. D. from the University of Connecticut, she leads teams focused on early-stage clinical development and statistical innovation for new cancer treatments, having progressed through several leadership roles within the company.
She has co-authored multiple publications on innovative statistical methods for clinical trials, including Bayesian trial designs and sample size re-estimation techniques.
Miaomiao Ge
Executive Director, Head of Experimental Medicine Oncology Biostatistics at Boehringer Ingelheim
Danbury, Connecticut, United States
Overview
Topics They Care About
Oncology Biostatistics
Leads the Experimental Medicine Oncology Biostatistics team at Boehringer Ingelheim, focusing on early-stage clinical development for new cancer treatments.
Clinical Trial Innovation
Co-authored research on innovative statistical methods, such as Bayesian basket trial designs, to improve the efficiency and design of clinical studies.
Statistical Methodology
Focuses on leveraging advanced statistical methods to shape healthcare decisions, particularly for market access and data-driven outcomes in drug development.
Media Appearances
Miaomiao has no verified media appearances
Work History
10-2025
Executive Director, Head of Experimental Medicine Oncology Biostatistics at Boehringer Ingelheim
5-2021 - 10-2025
Director at Boehringer Ingelheim
6-2018 - 5-2021
Senior Associate Director, Team Lead of Statistics at Boehringer Ingelheim
1-2009 - 8-2011
Student Fellow at Pfizer
Education
2006 - 2011
Ph.D. from University of Connecticut
2002 - 2006
B.S. from Nanjing University
More Information
Social Presence :
Prographics :
Exp : 10
Location : Danbury, Connecticut, United States
Job Level : Senior
Designation : Executive Director, Head of Experimental Medicine Oncology Biostatistics at Boehringer Ingelheim
